LIFETECH SCI.DL-00000125

81X · F · Healthcare / Medical Devices

0.164EUR+0.00 (+1.23%)

Price History

Full chart

Market Stats

Previous Close0.162

Open0.164

Day Range0.164 – 0.164

52-Week Range0.132 – 0.24

Volume0

Market Cap594.10M

P/E (TTM)0.00

Forward P/E0.00

EPS0.00

Dividend Yield0.00%

Beta0.33

50-Day Avg0.1402

200-Day Avg0.1659

About

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. It is also involved in biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.

Company Details

SectorHealthcare
IndustryMedical Devices
CEOMr. Yuehui Xie
Employees1.25K
HeadquartersLifeTech Scientific Building, Shenzhen, China, 518063, Germany
Websitehttps://www.lifetechmed.com

Leadership

Mr. Yuehui XieExecutive Chairman & CEO · b. 1969
Mr. Jianxiong Liu ACCACFO, Executive VP & Company Secretary · b. 1971
Ms. Xingmei RuanChief Compliance Officer · b. 1984
Ms. Liping WuExecutive Director · b. 1981
Mr. Yu FangExecutive Director · b. 1979

Financials

Income Statement

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	925.33M	1.10B	1.27B	1.30B	1.37B
Growth (%)	-	+18.59%	+15.48%	+2.88%	+5.07%
Cost of Revenue	177.80M	223.38M	271.54M	322.26M	350.67M
Gross Profit	747.53M	873.93M	995.64M	981.43M	1.02B
Gross Margin	80.79%	79.64%	78.57%	75.28%	74.40%
Operating Expense	420.86M	530.95M	701.18M	800.76M	843.23M
Operating Income	326.67M	342.98M	294.46M	180.68M	175.88M
Operating Margin	35.30%	31.26%	23.24%	13.86%	12.84%
EBITDA	-	445.78M	253.46M	288.88M	294.76M
EBITDA Margin	-	40.63%	20.00%	22.16%	21.52%
Net Income	292.47M	325.34M	263.24M	222.39M	147.83M
Net Income Margin	31.61%	29.65%	20.77%	17.06%	10.79%
R&D	145.89M	208.48M	297.92M	302.92M	242.66M
R&D as % of Total Revenue	15.77%	19.00%	23.51%	23.24%	17.72%
Interest Expense	2.61M	632.00K	722.00K	1.89M	210.00K
Interest Expense % of Total Revenue	0.28%	0.06%	0.06%	0.14%	0.02%

Balance Sheet

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	3.18B	3.69B	4.70B	4.90B	5.01B
Total Liabilities	653.61M	769.05M	1.37B	1.42B	1.54B
Total Equity	2.50B	2.90B	3.37B	3.49B	3.51B
Cash	1.12B	833.79M	979.31M	665.75M	719.32M

Cash Flow

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	441.09M	388.32M	418.05M	321.46M	549.28M
Capital Expenditure	343.29M	335.47M	292.69M	283.00M	150.25M
Free Cash Flow	97.81M	52.84M	125.36M	38.46M	399.03M
FCF to OCF	22.17%	13.61%	29.99%	11.96%	72.65%

Key Statistics & Ratios

Market Cap594.10M

Enterprise Value504.82M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.46

Price / Book1.40

EPS0.00

Book Value0.0944

Revenue (TTM)1.29B

Gross Profit (TTM)987.25M

EBITDA292.66M

Profit Margin4.51%

Operating Margin3.73%

Return on Equity0.64%

Return on Assets2.32%

Shares Outstanding4.40B

Shares Float3.58B

Beta0.33

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%